Acer Therapeutics Inc. (ACER)

NASDAQ: ACER · IEX Real-Time Price · USD
2.13
+0.56 (35.67%)
Dec 9, 2022 4:00 PM EST - Market closed
35.67%
Market Cap 26.36M
Revenue (ttm) 360,000
Net Income (ttm) -21.27M
Shares Out 16.09M
EPS (ttm) -1.39
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,340,603
Open 1.7
Previous Close 1.57
Day's Range 1.68 - 2.3
52-Week Range 1.11 - 3.77
Beta 1.20
Analysts Buy
Price Target 9.86 (+362.9%)
Earnings Date Nov 18, 2022

About ACER

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for t... [Read more]

Industry Pharmaceuticals
Founded 2013
CEO Christopher Schelling
Employees 41
Stock Exchange NASDAQ
Ticker Symbol ACER
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for ACER stock is "Buy." The 12-month stock price forecast is 9.86, which is an increase of 362.91% from the latest price.

Price Target
$9.86
(362.91% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Acer Therapeutics Announces $1.5M Private Placement

NEWTON, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, r...

1 week ago - GlobeNewsWire

Acer Therapeutics Reports Q3 2022 Financial Results and Provides Corporate Update

NEWTON, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, r...

3 weeks ago - GlobeNewsWire

Acer Therapeutics Receives Notice of Allowance of Key US Patent Application Covering EDSIVO™ (celiprolol)

Notice of allowance of celiprolol method of treatment of vEDS patent application strengthens proprietary position in U.S. until 2038 Notice of allowance of celiprolol method of treatment of vEDS patent ...

1 month ago - GlobeNewsWire

Acer Therapeutics Announces University of North Carolina Receives Department of Defense Grant to Support the Proposed...

$3 million awarded to University of North Carolina (UNC) to support a proposed 180-patient, randomized, placebo-controlled trial in trauma patients

2 months ago - GlobeNewsWire

Acer Therapeutics Announces Expansion of ACER-801 (osanetant) Development Indications to Include Post-Traumatic Stres...

Licensed exclusive worldwide rights from Emory University to patents and patent applications for certain methods of treating or preventing post-traumatic stress disorder (PTSD) with osanetant

2 months ago - GlobeNewsWire

Acer Therapeutics and Relief Therapeutics Announce Receipt of Notice of Allowance of US Patent Application Covering a...

Notice of allowance covering these claims further strengthens ACER-001 proprietary position in US; patent expected to be issued in Q4 2022 and expire in 2038 Notice of allowance covering these claims fu...

2 months ago - GlobeNewsWire

Acer Therapeutics to Participate in August and September 2022 Investor Conferences

NEWTON, Mass., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, r...

3 months ago - GlobeNewsWire

Acer Therapeutics Reports Q2 2022 Financial Results and Provides Corporate Update

NEWTON, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, r...

3 months ago - GlobeNewsWire

Relief Therapeutics and Acer Therapeutics Announce that the European Commission Has Granted Orphan Drug Designation f...

Orphan designation provides potential for up to 10-year market exclusivity in the EU upon regulatory approval Orphan designation provides potential for up to 10-year market exclusivity in the EU upon re...

3 months ago - GlobeNewsWire

New Strong Sell Stocks for July 28th

ACER, BAK, and CJPRY have been added to the Zacks Rank #5 (Strong Sell) List on July 28, 2022.

Other symbols: BAK
4 months ago - Zacks Investment Research

Acer Therapeutics and Relief Therapeutics Announce ACER-001 IND Submission for the Treatment of Maple Syrup Urine Dis...

Phase 2a trial initiation planned for the first half of 2023 subject to IND clearance and available capital Phase 2a trial initiation planned for the first half of 2023 subject to IND clearance and avai...

4 months ago - GlobeNewsWire

Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Tre...

Prescription Drug User Fee Act (PDUFA) target action date set for January 15, 2023 Prescription Drug User Fee Act (PDUFA) target action date set for January 15, 2023

4 months ago - GlobeNewsWire

Acer Therapeutics Announces Resubmission of New Drug Application for ACER-001 for Treatment of UCDs

Acer has notified the FDA in the resubmission that the third-party contract packaging manufacturer is ready for inspection Acer has notified the FDA in the resubmission that the third-party contract pac...

4 months ago - GlobeNewsWire

New Strong Sell Stocks for July 15th

ACER, HMN, and STT have been added to the Zacks Rank #5 (Strong Sell) List on July 15, 2022.

Other symbols: HMNSTT
4 months ago - Zacks Investment Research

Acer Therapeutics and Relief Therapeutics Announce That the China National Intellectual Property Administration (CNIP...

Key patent strengthens proprietary position in China until August 2031 Key patent strengthens proprietary position in China until August 2031

5 months ago - GlobeNewsWire

New Strong Sell Stocks for July 8th

ACER, CAH, and DRI have been added to the Zacks Rank #5 (Strong Sell) List on July 8, 2022.

Other symbols: CAHDRI
5 months ago - Zacks Investment Research

New Strong Sell Stocks for June 28th

ACER, BA, and LOB have been added to the Zacks Rank #5 (Strong Sell) List on June 28, 2022.

Other symbols: BALOB
5 months ago - Zacks Investment Research

New Strong Sell Stocks for June 23rd

ACER, PRG, and ALX have been added to the Zacks Rank #5 (Strong Sell) List on June 23, 2022.

Other symbols: ALXPRG
5 months ago - Zacks Investment Research

Acer Therapeutics (ACER) Gets CRL for Urea Cycle Disorders Drug

Acer Therapeutics' (ACER) new drug application for ACER-001 to treat urea cycle disorders faces rejection from the FDA. Share price falls 21% following the announcement.

5 months ago - Zacks Investment Research

FDA Rejects Acer Therapeutics - Relief Therapeutics' Urea Cycle Disorder Candidate

The FDA issued a Complete Response Letter regarding the marketing application for Acer Therapeutics Inc (NASDAQ: ACER) and its collaboration partner, Relief Therapeutics Holding SA's (OTC: RLFTF) ACER-0...

5 months ago - Benzinga

New Strong Sell Stocks for June 21st

ALYA, ALGN, and ACER have been added to the Zacks Rank #5 (Strong Sell) List on June 21, 2022.

Other symbols: ALGNALYA
5 months ago - Zacks Investment Research

Acer Therapeutics Announces Promotion of Tanya Hayden to Chief Operating Officer

NEWTON, Mass., June 21, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious ra...

5 months ago - GlobeNewsWire

Acer Therapeutics and Relief Therapeutics Announce Update on U.S. FDA Review of New Drug Application (NDA) for ACER-001

Citing the need to inspect a third-party contract packaging manufacturer, the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL)

5 months ago - GlobeNewsWire

New Strong Sell Stocks for June 15th

ACER, AHCHY, and AVVID have been added to the Zacks Rank #5 (Strong Sell) List on June 15, 2022.

5 months ago - Zacks Investment Research

New Strong Sell Stocks for June 9th

ALX, ACER, and SBFG have been added to the Zacks Rank #5 (Strong Sell) List on June 9, 2022.

Other symbols: ALXSBFG
6 months ago - Zacks Investment Research